0001493152-24-011034.txt : 20240322
0001493152-24-011034.hdr.sgml : 20240322
20240322180015
ACCESSION NUMBER: 0001493152-24-011034
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220315
FILED AS OF DATE: 20240322
DATE AS OF CHANGE: 20240322
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Callahan Jennifer L.
CENTRAL INDEX KEY: 0001883523
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40874
FILM NUMBER: 24776468
MAIL ADDRESS:
STREET 1: C/O CINGULATE INC.
STREET 2: 1901 W. 47TH PLACE
CITY: KANSAS CITY
STATE: KS
ZIP: 66205
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cingulate Inc.
CENTRAL INDEX KEY: 0001862150
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 863825535
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1901 W. 47TH PLACE
CITY: KANSAS CITY
STATE: KS
ZIP: 66205
BUSINESS PHONE: (913) 942-2300
MAIL ADDRESS:
STREET 1: 1901 W. 47TH PLACE
CITY: KANSAS CITY
STATE: KS
ZIP: 66205
4
1
ownership.xml
X0508
4
2022-03-15
0
0001862150
Cingulate Inc.
CING
0001883523
Callahan Jennifer L.
1901 W. 47TH PLACE
KANSAS CITY
KS
66205
0
1
0
0
SVP and CFO
0
Common Stock
2022-03-15
4
P
0
55
27.10
A
2333
D
Warrant to Purchase Common Stock
120
2022-03-15
4
P
0
1500
0.3007
A
2021-12-10
2026-12-10
Common Stock
75
21030
D
The number of shares and price reflect the 1-for-20 reverse stock split of the Issuer's issued and outstanding shares of common stock, which became effective on November 30, 2023.
Total number of securities includes purchases reflected on Forms 4 filed subsequent to the purchases this Form 4 covers.
The price reported in Column 8 is a weighted average price. These warrants were purchased in multiple transactions at prices ranging from $0.2999 to $0.3094 per warrant, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of warrants purchased at each separate price within the ranges set forth herein.
Jennifer L. Callahan
2024-03-22